Evonik Industries (EVK) Q2 2024 earnings summary

Executive summary

• Adjusted EBITDA rose 28% year-over-year to €578 million in Q2 2024, with all divisions outperforming expectations and strong free cash flow generation.

• Strategy focused on targeted investments, internal cost-saving measures, and the "Evonik Tailor Made" restructuring program, which aims for up to 2,000 job cuts and €400 million annual cost savings by 2026.

• No M&A activity planned for 2024 and 2025; focus remains on internal optimization and disciplined organic investments.

Financial highlights

• Q2 2024 sales were €3,930 million, up 1% year-over-year; adjusted EBITDA reached €578 million (+28%), and adjusted net income rose 90% to €234 million.

• Free cash flow for H1 2024 reached €344 million, over €500 million higher than the prior year, driven by improved earnings and lower capex.

• Adjusted EBITDA margin improved to 14.7% in Q2 2024 from 11.6% a year ago.

• Net financial debt increased to €3,611 million, mainly due to dividend payments, but leverage ratio declined due to higher EBITDA.

• Full-year free cash flow expected to be higher year-on-year, with more balanced quarterly distribution.

Outlook and guidance

• 2024 adjusted EBITDA guidance raised to €1.9–2.2 billion, with the lower end increasingly unlikely.

• Sales expected between €15–17 billion for FY 2024; all divisions anticipate higher earnings than prior year.

• Free cash flow conversion rate targeted around 40% for 2024; capex expected around €750 million.

• 2025 expected to benefit from €150 million in Tailor Made savings, €100 million from animal nutrition restructuring, and €50 million from lower energy costs.